Warriors Heart and Grunt Style Bring Recovery Stories to Life with Healing Mural and Art Gallery
Warriors Heart and Grunt Style reveal public art display by military, veterans and first responders Memorial Day thru Veterans Day.
'This collaborative mural and artwork are a public testament to healing, purpose, and the strength it takes to come home from the battles within.'— Christina Moreno, Warriors Heart Texas Executive Director
SAN ANTONIO, TX, UNITED STATES, May 20, 2025 / EINPresswire.com / -- Warriors Heart announces the Memorial Day weekend unveiling of a new healing mural titled, ' Service is a Lifestyle ' and 'Warriors HeArt Gallery' at the Grunt Style headquarters in downtown San Antonio, Texas. This public art display will be featured Memorial Day weekend through Veterans Day to shine a light on the often-unseen battles Warriors (military, veterans and first responders) face long after their service — and how creative expression becomes a path to healing for those struggling with addiction, PTSD and co-occurring issues.
Warriors Heart Texas Executive Director Christina Moreno emphasizes, 'This collaborative mural and artwork are a public testament to healing, purpose, and the strength it takes to come home from the battles within.'
Created by Warriors reclaiming their lives, the 'Warriors HeArt Gallery' invites the community to witness the transformation that happens when creativity becomes part of recovery. Many of the art pieces will feature QR codes linking to audio recordings of the Warriors' personal stories behind their creations — offering visitors a deeper, more intimate connection to the healing journeys represented in the gallery.
The mural and more than 60 pieces of artwork were created by Warriors - many who have completed Warriors Heart's specialized 42-day inpatient treatment program - along with contributions from Warriors Heart staff. Each piece reflects a personal story of service, struggle, and recovery through art.
Art therapy is an integral part of Warriors Heart's treatment, where clients work closely with the clinical team to use creative expression as a way to process emotions, confront trauma, and support their healing journey.
The 'Service is a Lifestyle' mural and 'Warriors HeArt Gallery' represents the dedication of warriors to servicing their community. The helmets at the bottom represent the population Warriors Heart serves, which includes military, veterans and first responders.
Creative Art Instructor Dan Monreal explains the overall theme of this mural and special exhibit, 'The idea is that service is a lifestyle. That is the theme of the art event that we'll be having all the way thrown through to November. The idea is strength, honor, and stability.'
Monreal further clarifies the mural's American eagle theme, 'The design idea came from of a painting that was done a few years back by a client that came through our program. The American eagle seems to be one of those symbolic images that represent them and their strengths and their honor. So, we thought it was fitting to incorporate the American eagle into this storefront design, along with the paint brushes, the palette of color, tubes of paint that we normally always go through when we're painting something in the Warriors Heart Art studio.'
Monreal adds, 'When warriors go through our program, we want them to go in and celebrate themselves in a way that they'll be able to carry the art idea with them back home, share it with friends, family members, strengthen their sobriety, and then just enjoy art because art is such a beautiful therapy.'
To make a further positive impact on the community, the 'Warriors HeArt Gallery' artwork will also be available for auction towards the end of the exhibit. All proceeds will go to Irreverent Warriors ( https://irreverentwarriors.com ) and Warriors Heart ( https://warriorsheart.com/connect ) to help more Warriors heal.
ABOUT: WARRIORS HEART (Bandera, Texas near San Antonio and Milford, Virginia, near Richmond and Washington D.C.) is the first and only private and accredited treatment program in the U.S. exclusively for 'warriors' (active duty military, veterans, first responders and EMTs/paramedics) faced with the self-medicating struggles of alcohol addiction, prescription and drug addiction, PTSD (post-traumatic stress disorder), mild TBI (Traumatic Brain Injury) and other co-occurring issues in a private, 100-bed facility on a 543-acre ranch in Bandera, Texas and 60-bed facility in Milford, Virginia. Along with a minimum 42-day peer-to-peer residential treatment program, Warriors Heart offers a full continuum of care with the option of Detox, Residential Treatment (inpatient), Day Treatment, Outpatient (IOP), Sober Living, TMS (brain treatment) and Aftercare. Warrior Heart is accredited by the Joint Commission, and is a member of the NAATP (National Association of Addiction Treatment Providers). As a 'Preferred In-Network Community Care Provider', Warriors Heart accepts TRICARE and most insurance. Warriors Heart's work has been featured on the TODAY Show, CBS Health Watch, A&E Intervention, National Defense Radio Show, NPR, Shawn Ryan Show, Dr. Drew Midday Live, and in FOXNews, TIME, Forbes, Addiction Pro magazine, Stars and Stripes, Task & Purpose, Military Families Magazine and many more. There is a 24-hour Warriors Heart hotline (866-955-4035) answered by warriors. For more information, visit https://warriorsheart.com/connect
ABOUT: GRUNT STYLE is a patriotic and veteran-operated apparel brand designed for a new class of warriors: first responders, military veterans, law enforcement, as well as their friends and families. With over 400 employees, the company works hard to deliver the highest quality, most patriotic apparel on the planet that's backed by an unbeatable lifetime guarantee. Headquartered in San Antonio, Texas, Grunt Style stands behind its products, its service, and our country. Visit https://www.gruntstyle.com and join the conversation on Facebook, Twitter, and Instagram at @GruntStyle.
MEDIA CONTACTS:
Warriors Heart: Liz Kelly: 310-987-7207
Grunt Style: Clarissa Castaneda, [email protected]
Liz H Kelly
Goody PR
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
An Uproar at the NIH
The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the best in culture. Sign up for it here. Updated at 10:26 a.m. on June 9, 2025 Since winning President Donald Trump's nomination to serve as the director of the National Institutes of Health, Jay Bhattacharya—a health economist and prominent COVID contrarian who advocated for reopening society in the early months of the pandemic—has pledged himself to a culture of dissent. 'Dissent is the very essence of science,' Bhattacharya said at his confirmation hearing in March. 'I'll foster a culture where NIH leadership will actively encourage different perspectives and create an environment where scientists, including early-career scientists and scientists that disagree with me, can express disagreement, respectfully.' Two months into his tenure at the agency, hundreds of NIH officials are taking Bhattacharya at his word. More than 300 officials, from across all of the NIH's 27 institutes and centers, have signed and sent a letter to Bhattacharya that condemns the changes that have thrown the agency into chaos in recent months—and calls on their director to reverse some of the most damaging shifts. Since January, the agency has been forced by Trump officials to fire thousands of its workers and rescind or withhold funding from thousands of research projects. Tomorrow, Bhattacharya is set to appear before a Senate appropriations subcommittee to discuss a proposed $18 billion slash to the NIH budget—about 40 percent of the agency's current allocation. The letter, titled the Bethesda Declaration (a reference to the NIH's location in Bethesda, Maryland), is modeled after the Great Barrington Declaration, an open letter published by Bhattacharya and two of his colleagues in October 2020 that criticized 'the prevailing COVID-19 policies' and argued that it was safe—even beneficial—for most people to resume life as normal. The approach that the Great Barrington Declaration laid out was, at the time, widely denounced by public-health experts, including the World Health Organization and then–NIH director Francis Collins, as dangerous and scientifically unsound. The allusion in the NIH letter, officials told me, isn't meant glibly: 'We hoped he might see himself in us as we were putting those concerns forward,' Jenna Norton, a program director at the National Institute of Diabetes and Digestive and Kidney Diseases, and one of the letter's organizers, told me. None of the NIH officials I spoke with for this story could recall another time in their agency's history when staff have spoken out so publicly against a director. But none of them could recall, either, ever seeing the NIH so aggressively jolted away from its core mission. 'It was time enough for us to speak out,' Sarah Kobrin, a branch chief at the National Cancer Institute, who has signed her name to the letter, told me. To preserve American research, government scientists—typically focused on scrutinizing and funding the projects most likely to advance the public's health—are now instead trying to persuade their agency's director to help them win a political fight with the White House. In an emailed statement, Bhattacharya said, 'The Bethesda Declaration has some fundamental misconceptions about the policy directions the NIH has taken in recent months, including the continuing support of the NIH for international collaboration. Nevertheless, respectful dissent in science is productive. We all want the NIH to succeed.' A spokesperson for HHS also defended the policies the letter critiqued, arguing that the NIH is 'working to remove ideological influence from the scientific process' and 'enhancing the transparency, rigor, and reproducibility of NIH-funded research.' The agency spends most of its nearly $48 billion budget powering science: It is the world's single-largest public funder of biomedical research. But since January, the NIH has canceled thousands of grants—originally awarded on the basis of merit—for political reasons: supporting DEI programming, having ties to universities that the administration has accused of anti-Semitism, sending resources to research initiatives in other countries, advancing scientific fields that Trump officials have deemed wasteful. Prior to 2025, grant cancellations were virtually unheard-of. But one official at the agency, who asked to remain anonymous out of fear of professional repercussions, told me that staff there now spend nearly as much time terminating grants as awarding them. And the few prominent projects that the agency has since been directed to fund appear either to be geared toward confirming the administration's biases on specific health conditions, or to benefit NIH leaders. 'We're just becoming a weapon of the state,' another official, who signed their name anonymously to the letter, told me. 'They're using grants as a lever to punish institutions and academia, and to censor and stifle science.' NIH officials have tried to voice their concerns in other ways. At internal meetings, leaders of the agency's institutes and centers have questioned major grant-making policy shifts. Some prominent officials have resigned. Current and former NIH staffers have been holding weekly vigils in Bethesda, commemorating, in the words of the organizers, 'the lives and knowledge lost through NIH cuts.' (Attendees are encouraged to wear black.) But these efforts have done little to slow the torrent of changes at the agency. Ian Morgan, a postdoctoral fellow at the NIH and one of the letter's signers, told me that the NIH fellows union, which he is part of, has sent Bhattacharya repeated requests to engage in discussion since his first week at the NIH. 'All of those have been ignored,' Morgan said. By formalizing their objections and signing their names to them, officials told me, they hope that Bhattacharya will finally feel compelled to respond. (To add to the public pressure, Jeremy Berg, who led the NIH's National Institute of General Medical Sciences until 2011, is also organizing a public letter of support for the Bethesda Declaration, in partnership with Stand Up for Science, which has organized rallies in support of research.) Scientists elsewhere at HHS, which oversees the NIH, have become unusually public in defying political leadership, too. Last month, after Health Secretary Robert F. Kennedy Jr.—in a bizarre departure from precedent—announced on social media that he was sidestepping his own agency, the CDC, and purging COVID shots from the childhood-immunization schedule, CDC officials chose to retain the vaccines in their recommendations, under the condition of shared decision making with a health-care provider. Many signers of the Bethesda letter are hopeful that Bhattacharya, 'as a scientist, has some of the same values as us,' Benjamin Feldman, a staff scientist at the National Institute of Child Health and Human Development, told me. Perhaps, with his academic credentials and commitment to evidence, he'll be willing to aid in the pushback against the administration's overall attacks on science, and defend the agency's ability to power research. But other officials I spoke with weren't so optimistic. Many at the NIH now feel they work in a 'culture of fear,' Norton said. Since January, NIH officials have told me that they have been screamed at and bullied by HHS personnel pushing for policy changes; some of the NIH leaders who have been most outspoken against leadership have also been forcibly reassigned to irrelevant positions. At one point, Norton said, after she fought for a program focused on researcher diversity, some members of NIH leadership came to her office and cautioned her that they didn't want to see her on the next list of mass firings. (In conversations with me, all of the named officials I spoke with emphasized that they were speaking in their personal capacity, and not for the NIH.) Bhattacharya, who took over only two months ago, hasn't been the Trump appointee driving most of the decisions affecting the NIH—and therefore might not have the power to reverse or overrule them. HHS officials have pressured agency leadership to defy court orders, as I've reported; mass cullings of grants have been overseen by DOGE. And as much as Bhattacharya might welcome dissent, he so far seems unmoved by it. In early May, Berg emailed Bhattacharya to express alarm over the NIH's severe slowdown in grant making, and to remind him of his responsibilities as director to responsibly shepherd the funds Congress had appropriated to the agency. The next morning, according to the exchange shared with me by Berg, Bhattacharya replied saying that, 'contrary to the assertion you make in the letter,' his job was to ensure that the NIH's money would be spent on projects that advance American health, rather than 'on ideological boondoggles and on dangerous research.' And at a recent NIH town hall, Bhattacharya dismissed one staffer's concerns that the Trump administration was purging the identifying variable of gender from scientific research. (Years of evidence back its use.) He echoed, instead, the Trump talking point that 'sex is a very cleanly defined variable,' and argued that gender shouldn't be included as 'a routine question in order to make an ideological point.' The officials I spoke with had few clear plans for what to do if their letter goes unheeded by leadership. Inside the agency, most see few levers left to pull. At the town hall, Bhattacharya also endorsed the highly contentious notion that human research started the pandemic—and noted that NIH-funded science, specifically, might have been to blame. When dozens of staffers stood and left the auditorium in protest, prompting applause that interrupted Bhattacharya, he simply smiled. 'It's nice to have free speech,' he said, before carrying right on. Article originally published at The Atlantic
Atlantic
2 hours ago
- Atlantic
‘We're Just Becoming a Weapon of the State'
Since winning President Donald Trump's nomination to serve as the director of the National Institutes of Health, Jay Bhattacharya—a health economist and prominent COVID contrarian who advocated for reopening society in the early months of the pandemic—has pledged himself to a culture of dissent. 'Dissent is the very essence of science,' Bhattacharya said at his confirmation hearing in March. 'I'll foster a culture where NIH leadership will actively encourage different perspectives and create an environment where scientists, including early-career scientists and scientists that disagree with me, can express disagreement, respectfully.' Two months into his tenure at the agency, hundreds of NIH officials are taking Bhattacharya at his word. More than 300 officials, from across all of the NIH's 27 institutes and centers, have signed and sent a letter to Bhattacharya that condemns the changes that have thrown the agency into chaos in recent months—and calls on their director to reverse some of the most damaging shifts. Since January, the agency has been forced by Trump officials to fire thousands of its workers and rescind or withhold funding from thousands of research projects. Tomorrow, Bhattacharya is set to appear before a Senate appropriations subcommittee to discuss a proposed $18 billion slash to the NIH budget—about 40 percent of the agency's current allocation. The letter, titled the Bethesda Declaration (a reference to the NIH's location in Bethesda, Maryland), is modeled after the Great Barrington Declaration, an open letter published by Bhattacharya and two of his colleagues in October 2020 that criticized 'the prevailing COVID-19 policies' and argued that it was safe—even beneficial—for most people to resume life as normal. The approach that the Great Barrington Declaration laid out was, at the time, widely denounced by public-health experts, including the World Health Organization and then–NIH director Francis Collins, as dangerous and scientifically unsound. The allusion in the NIH letter, officials told me, isn't meant glibly: 'We hoped he might see himself in us as we were putting those concerns forward,' Jenna Norton, a program director at the National Institute of Diabetes and Digestive and Kidney Diseases, and one of the letter's organizers, told me. None of the NIH officials I spoke with for this story could recall another time in their agency's history when staff have spoken out so publicly against a director. But none of them could recall, either, ever seeing the NIH so aggressively jolted away from its core mission. 'It was time enough for us to speak out,' Sarah Kobrin, a branch chief at the National Cancer Institute, who has signed her name to the letter, told me. To preserve American research, government scientists—typically focused on scrutinizing and funding the projects most likely to advance the public's health—are now instead trying to persuade their agency's director to help them win a political fight with the White House. Bhattacharya, the NIH, and the Department of Health and Human Services did not respond immediately to a request for comment. The agency spends most of its nearly $48 billion budget powering science: It is the world's single-largest public funder of biomedical research. But since January, the NIH has canceled thousands of grants —originally awarded on the basis of merit—for political reasons: supporting DEI programming, having ties to universities that the administration has accused of anti-Semitism, sending resources to research initiatives in other countries, advancing scientific fields that Trump officials have deemed wasteful. Prior to 2025, grant cancellations were virtually unheard-of. But one official at the agency, who asked to remain anonymous out of fear of professional repercussions, told me that staff there now spend nearly as much time terminating grants as awarding them. And the few prominent projects that the agency has since been directed to fund appear either to be geared toward confirming the administration's biases on specific health conditions, or to benefit NIH leaders. 'We're just becoming a weapon of the state,' another official, who signed their name anonymously to the letter, told me. 'They're using grants as a lever to punish institutions and academia, and to censor and stifle science.' NIH officials have tried to voice their concerns in other ways. At internal meetings, leaders of the agency's institutes and centers have questioned major grant-making policy shifts. Some prominent officials have resigned. Current and former NIH staffers have been holding weekly vigils in Bethesda, commemorating, in the words of the organizers, ' the lives and knowledge lost through NIH cuts.' (Attendees are encouraged to wear black.) But these efforts have done little to slow the torrent of changes at the agency. Ian Morgan, a postdoctoral fellow at the NIH and one of the letter's signers, told me that the NIH fellows union, which he is part of, has sent Bhattacharya repeated requests to engage in discussion since his first week at the NIH. 'All of those have been ignored,' Morgan said. By formalizing their objections and signing their names to them, officials told me, they hope that Bhattacharya will finally feel compelled to respond. (To add to the public pressure, Jeremy Berg, who led the NIH's National Institute of General Medical Sciences until 2011, is also organizing a public letter of support for the Bethesda Declaration, in partnership with Stand Up for Science, which has organized rallies in support of research.) Scientists elsewhere at HHS, which oversees the NIH, have become unusually public in defying political leadership, too. Last month, after Health Secretary Robert F. Kennedy Jr.—in a bizarre departure from precedent—announced on social media that he was sidestepping his own agency, the CDC, and purging COVID shots from the childhood-immunization schedule, CDC officials chose to retain the vaccines in their recommendations, under the condition of shared decision making with a health-care provider. Many signers of the Bethesda letter are hopeful that Bhattacharya, 'as a scientist, has some of the same values as us,' Benjamin Feldman, a staff scientist at the National Institute of Child Health and Human Development, told me. Perhaps, with his academic credentials and commitment to evidence, he'll be willing to aid in the pushback against the administration's overall attacks on science, and defend the agency's ability to power research. But other officials I spoke with weren't so optimistic. Many at the NIH now feel they work in a 'culture of fear,' Norton said. Since January, NIH officials have told me that they have been screamed at and bullied by HHS personnel pushing for policy changes; some of the NIH leaders who have been most outspoken against leadership have also been forcibly reassigned to irrelevant positions. At one point, Norton said, after she fought for a program focused on researcher diversity, some members of NIH leadership came to her office and cautioned her that they didn't want to see her on the next list of mass firings. (In conversations with me, all of the named officials I spoke with emphasized that they were speaking in their personal capacity, and not for the NIH.) Bhattacharya, who took over only two months ago, hasn't been the Trump appointee driving most of the decisions affecting the NIH—and therefore might not have the power to reverse or overrule them. HHS officials have pressured agency leadership to defy court orders, as I've reported; mass cullings of grants have been overseen by DOGE. And as much as Bhattacharya might welcome dissent, he so far seems unmoved by it. In early May, Berg emailed Bhattacharya to express alarm over the NIH's severe slowdown in grant making, and to remind him of his responsibilities as director to responsibly shepherd the funds Congress had appropriated to the agency. The next morning, according to the exchange shared with me by Berg, Bhattacharya replied saying that, 'contrary to the assertion you make in the letter,' his job was to ensure that the NIH's money would be spent on projects that advance American health, rather than 'on ideological boondoggles and on dangerous research.' And at a recent NIH town hall, Bhattacharya dismissed one staffer's concerns that the Trump administration was purging the identifying variable of gender from scientific research. (Years of evidence back its use.) He echoed, instead, the Trump talking point that 'sex is a very cleanly defined variable,' and argued that gender shouldn't be included as 'a routine question in order to make an ideological point.' The officials I spoke with had few clear plans for what to do if their letter goes unheeded by leadership. Inside the agency, most see few levers left to pull. At the town hall, Bhattacharya also endorsed the highly contentious notion that human research started the pandemic—and noted that NIH-funded science, specifically, might have been to blame. When dozens of staffers stood and left the auditorium in protest, prompting applause that interrupted Bhattacharya, he simply smiled
Yahoo
3 hours ago
- Yahoo
My 5-year-old survived cancer – twice. Don't put politics before medical research.
Few issues in American politics have consistently united both parties like the fight against cancer. While funding levels and strategies may differ, Democrats and Republicans alike recognize that cancer doesn't discriminate – and neither should our commitment to defeat it. Under the Biden administration, the Cancer Moonshot was relaunched to accelerate progress toward a cure. More recently, President Donald Trump announced his 'Stargate' initiative, which aims to harness artificial intelligence in detecting and treating cancer, including through personalized mRNA vaccines. In the United States, cancer is the leading cause of death by disease for children after infancy. Across the political spectrum, there remains a shared hope: that no one should have to endure the pain of losing a loved one or fight this deadly disease. Yet today, that consensus is showing signs of strain. State legislatures across the country are advancing bills to ban or severely restrict the use of – and further research into – breakthrough technologies like mRNA, a technology that is driving promising advancements in cancer. What should be a story of American scientific innovation is being twisted into a political talking point. And it's putting lives at risk. Opinion: Biden's diagnosis shows two things. Cancer hits everyone and some forgot that. If the politicians pushing these bans spent even a few minutes inside a pediatric oncology unit, maybe they'd understand. They'd see floors filled with sick children on small bicycles, pulling IV poles behind them. Children in hospital beds, brave beyond measure. And parents clinging to hope. I've seen it firsthand. I'm a mother whose 5-year-old daughter has survived cancer – twice. My daughter Charlie is one of a small percentage of pediatric cancer patients whose tumors don't show up on standard blood tests. Her cancer went undetected for more than a year. By the time doctors found it, it had already spread to her liver. She was just 3 years old and had Stage 4 cancer. Once Charlie's cancer was detected, we rushed into treatment: high-dose chemotherapy, stem cell transplants and multiple surgeries. After months of treatment, we got the news every parent prays for: Charlie was cancer-free. But just a few months later, scans revealed a relapse. Two small nodules were found on her lung. Her baby brother was only two months old when we learned her cancer had returned. Relapse treatment was grueling. Charlie lost weight and muscle mass. She needed a feeding tube to stay nourished, hydrated and medicated. But through it all, she never lost her smile. Her strength became ours. And while we juggled caring for a newborn and two other children, we held onto hope, because science gave us a reason to. Thanks to expert care at Seattle Children's and research-backed protocols, she's once again cancer-free. She started preschool this year. She's coloring, laughing and chasing her siblings again. Every option we had was made possible by decades of public investment in research. Families who came before us joined clinical trials. Lawmakers chose to fund pediatric science and cancer research. That is the same kind of work mRNA research builds on today. Opinion alerts: Get columns from your favorite columnists + expert analysis on top issues, delivered straight to your device through the USA TODAY app. Don't have the app? Download it for free from your app store. Researchers are developing an mRNA-based diagnostic test that could catch cancers like hers earlier, when they're more treatable. The test uses mRNA from her original tumor to detect any circulating cancer cells through a simple blood draw. Catching a relapse early could be lifesaving. We first learned about this test in 2023, and knowing it's almost within reach brings us, and families like ours, so much hope. Beyond mRNA-based diagnostic tests, mRNA has also shown early promise as a therapy for cancer patients, enabling personalized treatment that could more effectively target one's tumor. That kind of innovation is exactly what's under threat right now. The role of mRNA technology in oncology has been studied for decades, and yet some lawmakers want to roll this progress back, arguing it is untested and unsafe. This technology, along with many innovations that come from federally supported medical research, is a critical source of hope for families around the world. I'm a doctor. So is my mother. When she got cancer, I realized how little that mattered. | Opinion When you're watching your child battle cancer, every advancement matters. I know firsthand how critical it is to catch cancer early and have access to every possible treatment option. When politicians politicize science – when they ban or restrict it based on misinformation and politics – they aren't protecting families like mine. They're limiting our options. They're slowing down the breakthroughs that could save lives. We can't afford to let misinformation and polarized politics dictate the future of lifesaving research. Thanks to innovation in medical research, Charlie is thriving today, but far too many kids are still fighting. Let's ensure science continues to move forward for all of our children. Emily Stenson is a childhood cancer advocate and the mother of 5-year-old two-time cancer survivor Charlie Stenson. She lives in Seattle. You can read diverse opinions from our USA TODAY columnists and other writers on the Opinion front page, on X, formerly Twitter, @usatodayopinion and in our Opinion newsletter. This article originally appeared on USA TODAY: Cancer research saved my child's life. Fund mRNA innovation | Opinion
